UCB: new indication in sight for Bimzelx in US

(CercleFinance.com) - UCB announced on Thursday that the US FDA had agreed to review its supplemental new drug application (sBLA) for Bimzelx in a potential new indication, hidradenitis suppurativa.


Bimzelx, already approved in the US for the treatment of psoriasis since last October, is also currently the subject of other FDA submissions in psoriatic arthritis, axial spondyloarthritis and ankylosing spondylitis.

Hidradenitis suppurativa is a chronic, acne-like inflammation that leaves scars in the armpits, groin, nipple area and anus.

Following this announcement, UCB shares rose by more than 2.3% on Thursday on the Brussels Stock Exchange, one of the strongest gains on the BEL 20 index.


Copyright (c) 2024 CercleFinance.com. All rights reserved.